In a rare success story from India’s research-driven startup ecosystem, cell and gene therapy pioneer ImmunoAct has achieved profitability in its first full year of operations—a significant milestone in a sector often challenged by long development cycles and capital-intensive scaling.
Backed by Laurus Labs, which holds a 34% equity stake, ImmunoAct reported revenues of ₹62 crore and a profit before tax of ₹12 crore in FY25, according to sources. This marks a dramatic leap from its ₹11 crore revenue in the previous fiscal year, highlighting rapid commercial traction and operational efficiency.
As one of India’s few biotech startups to turn profitable this early, ImmunoAct is setting a new benchmark for innovation-led enterprises in the country’s burgeoning life sciences sector.
